US Market News
2月前
Blackstone and TPG Complete Acquisition of HologicApril 7, 2026 9:10 AM
Business Wire
Accomplished MedTech leader Joe Almeida named Chief Executive Officer
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately.
“Hologic is an incredible company with a storied history of innovation and an unparalleled reputation as a leader in women’s health,” said Almeida. “I am thrilled to be joining at such a pivotal moment. With the backing of Blackstone and TPG, we are poised to take the organization to new heights, with a renewed sense of purpose and greater resources to invest in innovation and initiatives that will advance the mission of enabling healthier lives around the world.”
The transaction was announced on October 21, 2025, and was approved by Hologic stockholders on February 5, 2026. With the completion of the acquisition, Hologic stockholders will receive $76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to $3 per share in two payments of up to $1.50 each, for total consideration of up to $79 per share in cash. The non-tradable CVR would be paid, in whole or in part, following achievement of certain global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.
Ram Jagannath, Senior Managing Director and Global Head of Healthcare at Blackstone said, “Hologic has established itself as a global leader in advancing women’s health, with a proven track record of delivering life-changing medical technologies. We are thrilled to partner with Joe Almeida — an exceptional medical technology leader — alongside Hologic’s talented team and TPG to drive the company’s next phase of growth and innovation.”
“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide,” said Alex Albert, Partner at TPG and Co-Head of Healthcare for TPG Capital. “Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. Under Joe’s experienced and proven leadership, we are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.”
Almeida was most recently Chairman, President and Chief Executive Officer of Baxter International Inc., where he served from 2016 to early 2025. During his tenure, he led a strategic repositioning of the company, focusing on operational improvement, portfolio changes and medical product innovation.
Prior to Baxter, Almeida served as Chairman, President and CEO of Covidien plc until its acquisition by Medtronic in 2015. Before joining Covidien, he held senior leadership roles at Tyco Healthcare, and previously served in executive positions at Wilson Greatbatch Technologies, Acufex Microsurgical and Codman & Shurtleff, a division of Johnson & Johnson. A native of Brazil, Almeida holds a Bachelor of Science in mechanical engineering from Instituto Mauá de Tecnologia in São Paulo.
Almeida succeeds Stephen MacMillan, who recently retired from his role as Chairman, President and CEO after more than 12 years leading the organization.
Hologic’s common stock has ceased trading and will be delisted from the Nasdaq Stock Market.
About Hologic
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com.
About Blackstone
Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s $1.3 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.
About TPG
TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with $303 billion of assets under management and investment and operational teams around the world. TPG invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, and market solutions, and our unique strategy is driven by collaboration, innovation, and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities.
Cautionary Statement Regarding Forward-Looking Statements
This news release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “likely,” “future,” “strategy,” “potential,” “seeks,” “goal” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of closing the merger. These forward-looking statements are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
These forward-looking statements are subject to a number of risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, including without limitation, risks related to disruption of management time from ongoing business operations due to the transaction; the risk of any litigation relating to the transaction; the risk that the transaction could have an adverse effect on the ability of Hologic to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive less-than-anticipated payments with respect to the CVRs. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the Hologic Annual Report on Form 10-K for the fiscal year ended September 27, 2025 filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by Hologic from time to time with the SEC. These filings, when available, are available on the investor relations section of the Hologic website at https://investors.hologic.com or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by law.
Source: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260406579333/en/
Media Contacts:
For Hologic
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
For Blackstone
Matt Anderson (Matthew.Anderson@Blackstone.com)
OR
Hallie Dewey (Hallie.Dewey@Blackstone.com)
OR
Jennifer Heath (Jennifer.Heath@Blackstone.com)
For TPG
Courtney Power
media@tpg.com
Original: Blackstone and TPG Complete Acquisition of Hologic
US Market News
2月前
Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600April 6, 2026 5:51 PM
PR Newswire (US)
NEW YORK, April 6, 2026 /PRNewswire/ -- S&P MidCap 400 constituent Casey's General Stores Inc. (NASD: CASY) will replace Hologic Inc. (NASD: HOLX) in the S&P 500, S&P SmallCap 600 constituent DigitalOcean Holdings Inc. (NYSE: DOCN) will replace Casey's General Stores in the S&P MidCap 400, and Broadstone Net Lease Inc. (NYSE: BNL) will replace DigitalOcean Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 9. Affiliates of Blackstone Inc. and TPG Global are acquiring Hologic in a deal expected to be completed on or about April 7.Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex NameActionCompany NameTickerGICS SectorApr 9, 2026S&P 500AdditionCasey's General Stores CASYConsumer StaplesApr 9, 2026S&P 500DeletionHologicHOLXHealth CareApr 9, 2026S&P MidCap 400AdditionDigitalOcean HoldingsDOCNInformation TechnologyApr 9, 2026S&P MidCap 400DeletionCasey's General StoresCASYConsumer StaplesApr 9, 2026S&P SmallCap 600AdditionBroadstone Net LeaseBNLReal EstateApr 9, 2026S&P SmallCap 600DeletionDigitalOcean HoldingsDOCNInformation TechnologyABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.comMedia Inquiries
spdji.comms@spglobal.com
View original content:https://www.prnewswire.com/news-releases/caseys-general-stores-set-to-join-sp-500-digitalocean-holdings-to-join-sp-midcap-400-broadstone-net-lease-to-join-sp-smallcap-600-302735034.htmlSOURCE S&P Dow Jones Indices
Original: Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600
US Market News
3月前
1,5 milliard de femmes privées d’examens préventifs essentiels malgré une légère hausse des taux de dépistage à l’échelle mondialeMarch 17, 2026 4:49 PM
Business Wire
La cinquième édition de l’Indice mondial de la santé des femmes de Hologic (Hologic Global Women’s Health Index, GWHI) révèle que plus de la moitié des femmes dans le monde n’ont pas bénéficié d’un dépistage pour des pathologies majeures au cours de l’année écoulée.
Hologic et Gallup ont réuni des experts pour examiner les moyens de combler les écarts d’accès au dépistage.
Hologic, Inc. (Nasdaq : HOLX), leader mondial de la santé des femmes, a publié aujourd’hui des données indiquant que, si le recours au dépistage de certaines pathologies progresse à l’échelle mondiale, un déficit majeur en la matière persiste. En effet, plus de la moitié des femmes et des filles de 15 ans et plus, soit environ 1,5 milliard de personnes, n’ont pas bénéficié d’un dépistage du cancer, de l’hypertension artérielle, du diabète ou des infections sexuellement transmissibles (IST) au cours de l’année écoulée.
Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260317811106/fr/Hologic Global Women's Health Index Fifth Edition
Ces données sont issues de la cinquième édition de l'Indice mondial de la santé des femmes de Hologic, élaborée en partenariat avec Gallup. Basé sur une enquête annuelle menée auprès de 145 000 personnes dans 144 pays et territoires, cet indice évalue et suit les progrès réalisés en matière de santé et de bien-être des femmes à l'échelle mondiale.
Les données cumulées sur cinq ans de l’Indice montrent que la proportion de femmes ayant bénéficié d’un dépistage pour des pathologies évitables majeures a progressé dans certains pays. Toutefois, à l’échelle mondiale, les taux de dépistage demeurent à un niveau inacceptable et les avancées restent limitées. Plus précisément, au cours de la cinquième année :
13 % des femmes dans le monde ont déclaré avoir bénéficié d’un dépistage, quel qu’il soit, au cours des 12 derniers mois (soit une hausse d’un point par rapport à la première année).
39 % des femmes avaient bénéficié d’un dépistage de l’hypertension artérielle (soit une hausse de six points par rapport à la première année).
24 % des femmes avaient bénéficié d’un dépistage du diabète (soit une hausse de cinq points par rapport à la première année).
10 % des femmes avaient bénéficié d’un dépistage des infections sexuellement transmissibles (IST) (soit une baisse d’un point par rapport à la première année).
« Il est encourageant de constater, dans les données de l'indice de cette année, la progression nécessaire des taux de dépistage préventif. Toutefois, nous ne devons pas confondre progrès et réussite », a déclaré Stephen P. MacMillan, président-directeur général de Hologic. « Alors que 1,5 milliard de femmes sont toujours privées de dépistages potentiellement vitaux, les besoins en matière de santé des femmes sont plus urgents que jamais. Nous disposons désormais de cinq années de données qui montrent ce qui fonctionne ; il nous appartient à présent de transformer ces enseignements et ces échanges en actions concrètes », a-t-il ajouté.
Au-delà des dépistages médicaux, l’Indice met en lumière des enseignements majeurs concernant plusieurs dimensions de la santé des femmes. Voici les plus marquants :
La santé physique des femmes continue de se dégrader. Un tiers des femmes déclarent souffrir quotidiennement de douleurs physiques et près d'une sur quatre indique être confrontée à des problèmes de santé suffisamment graves pour perturber ses activités quotidiennes.
Des niveaux élevés d’inquiétude et de tristesse continuent de peser sur la santé émotionnelle des femmes. Au cours de la cinquième année, une proportion plus élevée de femmes a déclaré se sentir inquiète (42 %) et triste (28 %) qu'au cours de la première année, ce qui témoigne d'une aggravation des expériences émotionnelles négatives avec le temps.
Près d’un milliard de femmes déclarent ne pas se sentir en sécurité lorsqu’elles marchent seules la nuit. Deux tiers des femmes (67 %) déclarent se sentir en sécurité lorsqu'elles se promènent seules la nuit dans leur quartier, ce qui constitue un nouveau record. Cependant, près d'un milliard de femmes ne se sentent toujours pas en sécurité.
Un milliard de femmes peinent à subvenir à leurs besoins essentiels. Près de quatre femmes sur dix ont déclaré avoir été confrontées, au cours de l’année écoulée, à des périodes où elles ne pouvaient pas se permettre d’acheter de la nourriture, et près d’une sur trois a éprouvé des difficultés à assumer ses dépenses de logement.
L’indice convertit les réponses des femmes à des questions portant sur cinq dimensions de la santé en un score unique compris entre 0 (niveau le plus faible) et 100 (niveau le plus élevé). À l’échelle mondiale, le score atteint 54 sur 100 lors de la cinquième année, soit le même résultat qu'au début de l'étude, ce qui indique qu'aucune amélioration globale de la santé des femmes n'a été enregistrée ces dernières années. Au niveau national, les progrès sont contrastés : depuis la première année, les scores ont progressé dans 28 pays et reculé dans 10. Les résultats de la cinquième année s’échelonnent d’un maximum de 69 points à Taïwan (en tête du classement mondial pour la cinquième année consécutive) à un minimum de 32 points au Tchad. En tant que base de données pluriannuelle, représentative à l’échelle mondiale et centrée sur les expériences de santé déclarées par les femmes, l’indice offre aux décideurs une base factuelle solide pour orienter leurs politiques et leurs actions. Pour accélérer les progrès en matière de santé des femmes, il préconise :
Un engagement mondial en faveur de l’élargissement de l’accès au dépistage précoce, en particulier pour les pathologies qui touchent de manière disproportionnée les femmes.
Élaborer des stratégies nationales dédiées à la santé des femmes, définissant un parcours de santé et de bien-être tout au long de la vie.
Combler les lacunes de la recherche concernant les pathologies qui touchent de manière disproportionnée les femmes ou qui les affectent différemment.
Des experts mondiaux de la santé débattent des stratégies permettant de pallier le déficit de dépistage
L’indice sera officiellement présenté aujourd’hui lors d’un événement organisé par Hologic et accueilli au siège mondial de Gallup, à Washington, D.C. Des experts de la santé des femmes, des défenseurs du dépistage et des représentants du secteur sont attendus pour marquer les cinq ans de l’indice et examiner les défis sanitaires auxquels les femmes sont confrontées à travers le monde, notamment les inégalités d’accès au dépistage.
Parmi les intervenants figurent la Dre Mia Keeys, directrice de la santé mondiale et de l’innovation chez Hologic ; Jody Hoyos, présidente-directrice générale de la Prevent Cancer Foundation ; Ritu Sharma, directrice des politiques mondiales chez CARE USA ; ainsi que Janet Fleischman, consultante indépendante en santé mondiale et en égalité des sexes et collaboratrice senior non résidente au Centre de politique de santé mondiale du CSIS.
Pour plus d'informations et pour télécharger le rapport complet, rendez-vous sur WomensHealthIndex.com.
À propos de Hologic, Inc.
Hologic, Inc. est un leader mondial dans le domaine de la santé des femmes. L'entreprise conçoit des technologies médicales innovantes pour améliorer le dépistage, le diagnostic et le traitement des pathologies, et faire progresser les standards de soins dans le monde. Pour en savoir plus, rendez-vous sur www.hologic.com et suivez-nous sur LinkedIn, Facebook, X, Instagram et YouTube.
À propos de Gallup
Gallup fournit des analyses et des conseils stratégiques afin d’aider les dirigeants et les organisations à relever leurs défis les plus pressants. Fort de plus de 90 ans d’expérience et d’une présence mondiale, Gallup dispose d’une connaissance approfondie des attitudes et des comportements des populations à travers le monde, inégalée par toute autre organisation.
SOURCE : Hologic, Inc.
Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.
Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260317811106/fr/
Contact médias :
Bridget Perry
Directrice principal des communications d’entreprise
(+1) 617.997.3840
bridget.perry@hologic.com
Original: 1,5 milliard de femmes privées d’examens préventifs essentiels malgré une légère hausse des taux de dépistage à l’échelle mondiale
US Market News
3月前
1,5 Milliarden Frauen verpassen wichtige Vorsorgeuntersuchungen – trotz weltweit steigender Screening-RatenMarch 17, 2026 4:32 PM
Business Wire
Die fünfte Ausgabe des „Hologic Global Women’s Health Index“ zeigt, dass über die Hälfte der Frauen weltweit im vergangenen Jahr nicht auf wichtige Erkrankungen untersucht wurde
Hologic und Gallup bringen Experten zusammen, um über die Schließung von Lücken beim Zugang zu Vorsorgeuntersuchungen zu diskutieren
Hologic, Inc. (Nasdaq: HOLX), ein weltweit führendes Unternehmen im Bereich der Frauengesundheit, veröffentlichte heute Daten, aus denen hervorgeht, dass zwar die Zahl der Vorsorgeuntersuchungen bei Frauen weltweit gestiegen ist, jedoch nach wie vor eine große Lücke im Zugang zu Vorsorgeuntersuchungen besteht. Über die Hälfte der Frauen und Mädchen ab 15 Jahren – schätzungsweise 1,5 Milliarden Frauen – wurden im vergangenen Jahr nicht auf Krebs, Bluthochdruck, Diabetes oder sexuell übertragbare Infektionen (STIs) untersucht.
Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260317024885/de/Hologic Global Women's Health Index Fifth Edition
Die Daten sind Teil der fünften Ausgabe des Hologic Global Women’s Health Index, der in Zusammenarbeit mit Gallup entwickelt wurde. Basierend auf einer jährlichen Umfrage unter 145.000 Menschen in 144 Ländern und Gebieten verfolgt der Index die Fortschritte bei der Gesundheit und dem Wohlbefinden von Frauen weltweit.
Die Daten aus fünf Jahren zeigen, dass der Anteil der Frauen, die auf wichtige vermeidbare Erkrankungen untersucht wurden, in einigen Ländern gestiegen ist, doch auf globaler Ebene bleiben die Vorsorgequoten unannehmbar niedrig, und die Fortschritte waren begrenzt. Im Einzelnen im fünften Jahr:
13 % der Frauen weltweit gaben an, dass sie in den letzten 12 Monaten auf irgendeine Art von Krebs untersucht worden waren (ein Anstieg um 1 Prozentpunkt seit dem ersten Jahr)
39 % waren auf Bluthochdruck untersucht worden (ein Anstieg um 6 Prozentpunkte seit dem ersten Jahr)
24 % waren auf Diabetes untersucht worden (ein Anstieg um 5 Prozentpunkte seit dem ersten Jahr)
10 % waren auf sexuell übertragbare Infektionen untersucht worden (ein Rückgang um 1 Prozentpunkt seit dem ersten Jahr)
„Es ist ermutigend, in den diesjährigen Indexdaten den notwendigen Anstieg der Vorsorgeuntersuchungsraten zu sehen, aber wir dürfen Fortschritt nicht mit Erfolg verwechseln“, sagte Stephen P. MacMillan, Vorsitzender, Präsident und CEO von Hologic. „Da 1,5 Milliarden Frauen immer noch keine lebensrettenden Vorsorgeuntersuchungen in Anspruch nehmen, sind die Gesundheitsbedürfnisse von Frauen so dringend wie eh und je. Wir verfügen nun über Daten aus fünf Jahren, die aufzeigen, was funktioniert; jetzt müssen wir Daten und Diskussionen in Taten umsetzen.“
Über Gesundheitsvorsorgeuntersuchungen hinaus liefert der Index wichtige Erkenntnisse zu verschiedenen Aspekten der Frauengesundheit. Vor allem:
Die körperliche Gesundheit von Frauen leidet weiterhin. Ein Drittel der Frauen gab an, täglich unter körperlichen Schmerzen zu leiden, und fast jede Vierte berichtete von Gesundheitsproblemen, die so schwerwiegend sind, dass sie die täglichen Aktivitäten beeinträchtigen.
Ein hohes Maß an Sorgen und Traurigkeit wirkt sich negativ auf die emotionale Gesundheit von Frauen aus. Im fünften Jahr gaben mehr Frauen an, sich besorgt (42 %) und traurig (28 %) zu fühlen als im ersten Jahr, was einen Anstieg negativer emotionaler Erfahrungen im Laufe der Zeit unterstreicht.
Fast 1 Milliarde Frauen fühlen sich unsicher, wenn sie nachts alleine unterwegs sind. Zwei Drittel der Frauen (67 %) gaben an, dass sie sich in ihrer Umgebung sicher fühlen, wenn sie nachts alleine unterwegs sind – ein neuer Höchststand. Dennoch fühlen sich fast 1 Milliarde Frauen weiterhin unsicher.
Eine Milliarde Frauen hat Schwierigkeiten, sich das Nötigste zu leisten. Fast 4 von 10 Frauen gaben an, dass es im vergangenen Jahr Zeiten gab, in denen sie sich keine Lebensmittel leisten konnten, und fast jede Dritte hatte Schwierigkeiten, ihre Wohnkosten zu decken.
Der Index wandelt die Antworten der Frauen auf Fragen zu fünf Gesundheitsdimensionen in einen einzigen Wert zwischen 0 (niedrigster) und 100 (höchster) um. Weltweit lag der Indexwert im fünften Jahr bei 54 von 100 Punkten, genau wie im ersten Jahr, was darauf hindeutet, dass sich die globale Gesundheit von Frauen in den letzten Jahren insgesamt nicht verbessert hat. Auf Länderebene waren die Fortschritte uneinheitlich: Seit dem ersten Jahr sind die Indexwerte in 28 Ländern gestiegen und in 10 gesunken. Die Werte im fünften Jahr reichen von einem Höchstwert von 69 in Taiwan – das zum fünften Mal in Folge weltweit an der Spitze lag – bis zu einem Tiefstwert von 32 im Tschad. Als großer, mehrjähriger, weltweit repräsentativer Datensatz, der sich auf die von Frauen berichteten Gesundheitserfahrungen konzentriert, bietet der Index Entscheidungsträgern eine klare Faktengrundlage für ihr Handeln. Um Fortschritte in der Frauengesundheit zu beschleunigen, fordert er:
Ein globales Engagement zur Verbesserung des Zugangs zu Früherkennung, insbesondere bei Erkrankungen, von denen Frauen überproportional betroffen sind.
Die Entwicklung nationaler Strategien zur Frauengesundheit, die einen lebenslangen Fahrplan für Gesundheit und Wohlbefinden festlegen.
Die Schließung von Forschungslücken bei Erkrankungen, die Frauen überproportional betreffen oder sich auf sie anders auswirken.
Globale Gesundheitsexperten diskutieren Strategien zur Schließung der Vorsorge-Lücke
Der Index wird heute im Rahmen einer von Hologic veranstalteten Veranstaltung im Gallup-Hauptsitz in Washington, D.C., vorgestellt. Die Veranstaltung bringt Expertinnen für Frauengesundheit, Befürworterinnen von Vorsorgeuntersuchungen und Vertreterinnen der Industrie zusammen, um das fünfjährige Bestehen des Index zu feiern und die gesundheitlichen Herausforderungen zu erörtern, denen Frauen weltweit gegenüberstehen – einschließlich der Lücken beim Zugang zu Vorsorgeuntersuchungen.
Zu den Referenten gehören Dr. Mia Keeys, Direktorin für globale Gesundheit und Innovation bei Hologic; Jody Hoyos, CEO der Prevent Cancer Foundation; Ritu Sharma, Chief Global Policy Officer bei CARE USA; und Janet Fleischman, unabhängige Beraterin für globale Gesundheit und Geschlechtergerechtigkeit sowie nicht-residente Senior Associate am CSIS Global Health Policy Center.
Weitere Informationen und den vollständigen Bericht zum Herunterladen finden Sie unter WomensHealthIndex.com.
Über Hologic, Inc.
Hologic, Inc. ist ein weltweit führendes Unternehmen im Bereich der Frauengesundheit, das sich auf die Entwicklung innovativer medizinischer Technologien konzentriert, die Gesundheitsprobleme effektiv erkennen, diagnostizieren und behandeln und den Versorgungsstandard weltweit verbessern. Um mehr zu erfahren, besuchen Sie www.hologic.com und verbinden Sie sich mit uns auf LinkedIn, Facebook, X, Instagram und YouTube.
Über Gallup
Gallup bietet Analysen und Beratung, um Führungskräfte und Organisationen bei der Lösung ihrer dringlichsten Probleme zu unterstützen. Dank seiner mehr als 90-jährigen Erfahrung und seiner globalen Reichweite weiß Gallup mehr über die Einstellungen und Verhaltensweisen der Menschen weltweit als jede andere Organisation.
QUELLE: Hologic, Inc.
Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260317024885/de/
Medienkontakt
Bridget Perry
Senior Director, Konzernkommunikation
(+1) 617.997.3840
bridget.perry@hologic.com
Original: 1,5 Milliarden Frauen verpassen wichtige Vorsorgeuntersuchungen – trotz weltweit steigender Screening-Raten
US Market News
4月前
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health PortfolioFebruary 4, 2026 8:15 AM
Business Wire
Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice
Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/
Screening for cervical cancer is critically important to women’s health. In the United States, it is estimated that in 2026, approximately 13,490 new cases of invasive cervical cancer will be diagnosed, and about 4,200 women will die from the disease.1 However, many of these deaths are preventable with regular screening and appropriate follow-up on abnormal results. Timely follow-up is essential for early detection and treatment to reduce cervical cancer cases and deaths.1
“Hologic has been at the forefront of cervical cancer screening for decades, and the additional indication of the Aptima HPV Assay reflects our ongoing commitment to advancing women’s health through innovative, evidence-based solutions,” said Jennifer Schneiders, Ph.D., President of Diagnostic Solutions at Hologic. “Our commitment to providing comprehensive cervical health solutions that meet provider and patient needs is unwavering, and by offering providers more choice and flexibility, we can help them deliver the most personalized care for each patient.”
The additional indication for the Aptima HPV Assay expands Hologic’s offerings to now include Pap + HPV (co-testing), Pap testing, and HPV primary testing — three major FDA-approved and guideline-recommended methods for cervical cancer screening. This additional approval for the Aptima HPV Assay follows the clearance of the Genius® Digital Diagnostics System with the Genius® Cervical AI Algorithm, which leverages advanced digital imaging and artificial intelligence to help detect cytologic abnormalities and precancerous lesions.
The approval comes following the completion of one of the largest real-world evidence HPV screening studies, involving over 650,000 women across multiple U.S. health systems that reflect diverse, real-life patient populations and clinical settings. This innovative study compared the Aptima HPV Assay to an FDA-approved DNA-based HPV test for primary screening and found that the sensitivity of the Aptima HPV Assay is clinically comparable to the comparator test. The Aptima HPV Assay is effective for use in primary screening for the detection of CIN2+ and CIN3+.
While co-testing remains the most comprehensive screening modality — with more than 90% of providers reporting strong confidence for women ages 30 to 65, and data showing that co-testing (Pap + HPV) detected up to 95% of cervical cancers — Hologic's range of testing options gives providers greater flexibility in selecting an approach based on a patient’s age, access and risk factors.2-5
About Hologic’s Cervical Health Solutions
Hologic offers a broad portfolio for cervical cancer screening, supporting both cytology and molecular workflows from sample collection to results. The portfolio includes innovations such as the ThinPrep® Pap Test, the first liquid-based cytology test, the Aptima HPV Assay, the first and only approved mRNA-based HPV tests, and the Genius Digital Diagnostics System, the first and only FDA-cleared digital cytology system. These technologies are designed to support clinicians and laboratory professionals in the detection and prevention of cervical cancer, all backed by Hologic’s support and partnership. To learn more, please visit Hologic.com.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s and its subsidiaries’ products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, Aptima, ThinPrep, Genius and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners.
References: 1. American Cancer Society. Cancer Statistics Center. Accessed January 2026. https://cancerstatisticscenter.cancer.org/types/cervix. 2. Austin et al. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting. Am J Clin Patho 2018; 150:385-392 1. 3. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/cncy.21544. 4. Kaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV and Hybrid Capture 2). 5. Kruse G, et al. Provider beliefs in effectiveness and recommendations for primary HPV testing in 3 health-care systems. JNCI Cancer Spectrum. 2023;7(1).
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126336815/en/
Media Contact:
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Investor Contact:
Michael Watts
Corporate Vice President, Investor Relations
(+1) 858.410.8514
michael.watts@hologic.com
Original: Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
stocktrademan
11年前
$HOLX recent news/filings
bullish
## source: finance.yahoo.com
Sat, 20 Jun 2015 05:18:00 GMT ~ 1:18 am Hologic prices $1.0 bln of 5.250% Senior Notes due 2022
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#holx
*********************************************************
Fri, 19 Jun 2015 10:02:49 GMT ~ HOLOGIC INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/150619/holx8-k.html
*********************************************************
Fri, 19 Jun 2015 00:33:05 GMT ~ Hologic Announces Pricing of Offering of $1.0 Billion Aggregate Principal Amount of 5.250% Senior Notes Due 2022
[at noodls] - BEDFORD, Mass. , June 18, 2015 /PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced today that it has priced its previously announced private offering of $1.0 billion aggregate principal amount of 5.250% ...
read full: http://www.noodls.com/view/9D7B62CB2023037264197B9D58377B429E00C166
*********************************************************
Fri, 19 Jun 2015 00:12:00 GMT ~ Hologic Announces Pricing of Offering of $1.0 Billion Aggregate Principal Amount of 5.250% Senior Notes Due 2022
[PR Newswire] - BEDFORD, Mass., June 18, 2015 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that it has priced its previously announced private offering of $1.0 billion aggregate principal amount of 5.250% senior notes due 2022 at an issue price of $1,000 per $1,000. The 2022 notes will be unsecured obligations of the Company and will be guaranteed by certain of its direct and indirect subsidiaries. Hologic intends to use the net proceeds of the offering, plus available cash, to redeem its outstanding 6.25% senior notes due 2020 in the aggregate principal amount of $1.0 billion.
read full: http://finance.yahoo.com/news/hologic-announces-pricing-offering-1-001200054.html
*********************************************************
Thu, 18 Jun 2015 14:56:03 GMT ~ Hologic, Inc. -- Moody's assigns B1 to Hologic's new bond
read full: http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_328021&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20150618_PR_328021
*********************************************************
$HOLX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$HOLX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/HOLX/company-info
Ticker: $HOLX
OTC Market Place: Not Available
CIK code: 0000859737
Company name: Hologic, Inc.
Incorporated In: DE, USA
$HOLX share structure
## source: otcmarkets.com
Market Value: $10,749,911,664 a/o Jun 19, 2015
Shares Outstanding: 280,969,986 a/o Apr 24, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$HOLX extra dd links
Company name: Hologic, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=HOLX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=HOLX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=HOLX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/news - http://finance.yahoo.com/q/h?s=HOLX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/HOLX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=HOLX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/HOLX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Hologic%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Hologic%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Hologic%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/HOLX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000859737&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=HOLX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=HOLX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=HOLX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=HOLX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=HOLX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=HOLX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=HOLX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/HOLX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=HOLX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/HOLX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=HOLX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/HOLX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/HOLX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/HOLX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=HOLX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=HOLX
$HOLX DD Notes ~ http://www.ddnotesmaker.com/HOLX
mlkrborn
14年前
Good earnings & Buying a compay @ $82 a share! $19 NOW!
Hologic reports EPS in-line, revs in-line; guides Q3 EPS slightly below consensus, revs below consensus; reaffirms FY12 revs guidance; reaffirms FY13 EPS guidance; to acquire GPRO in an accretive transaction (see 6:33) (HOLX) 21.23 : Reports Q2 (Mar) earnings of $0.33 per share, excluding non-recurring items, in-line with the Capital IQ Consensus Estimate consensus of $0.33; revenues rose 7.4% year/year to $471.2 mln vs the $473.83 mln consensus. Co issues slight downside guidance for Q3, sees EPS of ~$0.34 vs. $0.35 Capital IQ Consensus Estimate; sees Q3 revs of $475-480 mln, excluding non-recurring items, vs. $482.29 mln Capital IQ Consensus Estimate. Co reaffirms guidance for FY12, sees FY12 revs of $1.9-$1.925 bln vs. $1.92 bln Capital IQ Consensus Estimate. Co reaffirms guidance for FY13, sees EPS of $1.36-1.38, excluding non-recurring items, vs. $1.52 Capital IQ Consensus Estimate. Co may not generate expected revenues and may incur expenses or charges or realize income or gains in fiscal 2012 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory conditions and related uncertainties, including the implementation of healthcare cost containment measures and healthcare reform legislation, as well as foreign currency fluctuations, which, along with other uncertainties facing the Company's business including those referenced elsewhere herein and its filings with the Securities and Exchange Commission, could adversely affect anticipated results. "We are once again very pleased we experienced year-over-year revenue growth in all four of our business segments and our operating results were in-line with expectations, given the second quarter is historically our slowest as a result of resetting deductibles and the timing of orders for capital equipment."
6:33AM Gen-Probe to be acquired by Hologic (HOLX) for $82.75/share in cash; HOLX expects transaction to be $0.20 accretive to adjusted EPS in first fiscal year after close (GPRO) 68.70 : Cos announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic (HOLX) will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of ~ $3.7 bln. The all-cash transaction is expected to be funded through available cash and additional financing of term loans and high yield securities. The transaction is expected to be completed in the second half of calendar 2012. The transaction is expected to be $0.20 accretive to Hologic's adjusted earnings per share in the first fiscal year after close and significantly more accretive thereafter. Hologic also expects the transaction to accelerate top and bottom line growth rates. The combined company expects to realize approximately $75 million in cost synergies within three years following the close of the transaction. In addition, the combined company expects to have strong free cash flows, which will be used primarily to reduce debt with the expectation to return to pre-transaction leverage levels within three years.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
BottomBounce
1年前
TruckingAngler
5年前
CA CHASE
6年前
ValueInvestor15
10年前
mustangowner
12年前
surf1944
13年前
SOUTHGAS
14年前
Penny Roger$
14年前
メールアドレスで登録
